GEHealthCareAnnouncesFirstPatientDosedinPhase2/3LUMINATrialforManganese-BasedMRIContrastAgentUnderFDAFastTrackDesignation,FurtherAdvancingItsInnovationPipelineofNovelImagingAgents
===2026/4/24 10:39:04===
Imaging, Advanced Visualization Solutions, Patient Care Solutions, and Pharmaceutical Diagnostics segments to help clinicians deliver more personalized, precise patient care. We are a ¥20.6 billion business with approximately 54,000 colleagues working to create a world where healthcare has no limits.
GE HealthCare is proud to be among2026FortuneWorld’s Most Admired Companies™.
Follow us onLinkedIn,Facebook,Instagram, or visit our website for ourlatest newsandperspectives.
1Contrast Agents of Magnetic Resonance Imaging and Future Perspective.Nanomaterials.Available at:https://pmc.ncbi.nlm.nih.gov/articles/PMC10343825/[europepmc.org]
2Recent Developments and Future Perspectives in Magnetic Resonance Imaging and Computed Tomography Contrast Media.Frontiers in Radiology.Available at:https://pmc.ncbi.nlm.nih.gov/articles/PMC12871431/
Contacts
GE HealthCare Media Contact:
David Morris
M: +44 7920 59
=*=*=*=*=*=
当前为第6/7页
下一页-上一页-
=*=*=*=*=*=
返回新闻列表
返回网站首页